Altamira Therapeutics Shares Outstanding History (CYTOF)
Altamira Therapeutics reported 4.7M shares outstanding at the end of fiscal 2024.
View full Altamira Therapeutics company overviewAltamira Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 4.7M | 3.2M | +215.48% |
| 2023 | 2023-12-31 | 1.5M | 1.4M | +2404.59% |
| 2022 | 2022-12-31 | 59,003 | 21,592 | +57.72% |
| 2021 | 2021-12-31 | 37,411 | −533,447 | −93.45% |
| 2020 | 2020-12-31 | 570,858 | −1.2M | −67.85% |
| 2018 | 2018-12-31 | 1.8M | −46.6M | −96.33% |
| 2017 | 2017-12-31 | 48.4M | 48.4M | +37499039.53% |
| 2019 | 2015-12-31 | 129 | — | — |
Altamira Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 5.7M | −2.2M | −28.14% |
| Q4 2024 | 2024-12-31 | 4.7M | 4.6M | +7801.43% |
| Q2 2024 | 2024-06-30 | 2.7M | 1.8M | +213.00% |
| Q4 2023 | 2023-12-31 | 1.5M | 1.4M | +3850.13% |
| Q2 2023 | 2023-06-30 | 8.0M | −5.7M | −41.70% |
| Q4 2022 | 2022-12-31 | 59,003 | −511,855 | −89.66% |
| Q2 2022 | 2022-06-30 | 853,213 | −922,626 | −51.95% |
| Q4 2021 | 2021-12-31 | 37,411 | −48.3M | −99.92% |
| Q2 2021 | 2021-06-30 | 13.6M | 13.6M | +10575969.77% |
| Q4 2020 | 2020-12-31 | 570,858 | — | — |
| Q4 2018 | 2018-12-31 | 1.8M | — | — |
| Q4 2017 | 2017-12-31 | 48.4M | — | — |
| Q4 2019 | 2015-12-31 | 129 | — | — |
Altamira Therapeutics shares outstanding trends
Over the last five reported fiscal years, Altamira Therapeutics's shares outstanding moved from 1.8M to 4.7M, a change of 2.9M. The latest reported quarter, Q2 2025, shows 5.7M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Altamira Therapeutics filings at SEC.gov ↗